Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases

[1]  Joseph O. Deasy,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .

[2]  C. Ng,et al.  Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. , 2010, Clinical colorectal cancer.

[3]  C. Ng,et al.  A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5‐fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver , 2010, Cancer.

[4]  Jianjun Luo,et al.  Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. , 2010, Anticancer research.

[5]  D. Iannitti,et al.  Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Advanced Hepatocellular Cancer: A Brown University Oncology Group Study , 2010, American journal of clinical oncology.

[6]  B. Neyns,et al.  Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. , 2008, Anticancer research.

[7]  Johan Fevery,et al.  Bilirubin in clinical practice: a review , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[8]  S. Buti,et al.  Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report. , 2007, Anti-cancer drugs.

[9]  R. D. de Vries,et al.  Serious delayed hypersensitivity reaction to oxaliplatin. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Agnès Laplanche,et al.  Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Hochster,et al.  Oxaliplatin: practical guidelines for administration. , 2004, Clinical journal of oncology nursing.

[12]  N. Kemeny,et al.  An update on hepatic arterial infusion chemotherapy for colorectal cancer. , 2003, The oncologist.

[13]  A. Chang,et al.  Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. , 2002, Surgical oncology.

[14]  M. Floeter,et al.  Acute oxaliplatin-induced peripheral nerve hyperexcitability. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Hiddemann,et al.  Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  L. Wiseman,et al.  Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. , 2000, Drugs.

[17]  M. Ducreux,et al.  Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure , 2007, Annals of Surgical Oncology.

[18]  B. Neyns,et al.  Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. , 2006, Anticancer research.